BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1421 related articles for article (PubMed ID: 28554738)

  • 1. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
    Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
    Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
    Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
    Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pathological analyses of transplant glomerulopathy cases.
    Shimizu T; Ishida H; Toki D; Nozaki T; Omoto K; Tanabe K; Honda K; Koike J
    Nephrology (Carlton); 2014 Jun; 19 Suppl 3():21-6. PubMed ID: 24842817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
    Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
    Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capillary deposition of complement C4d and C3d in pediatric renal allograft biopsies.
    Herman J; Lerut E; Van Damme-Lombaerts R; Emonds MP; Van Damme B
    Transplantation; 2005 May; 79(10):1435-40. PubMed ID: 15912116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of preformed donor-specific antibodies and C4d on early liver allograft function.
    Perera MT; Silva MA; Murphy N; Briggs D; Mirza DF; Neil DA
    Scand J Gastroenterol; 2013 Dec; 48(12):1444-51. PubMed ID: 24131305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
    Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
    Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies.
    Callemeyn J; Lerut E; de Loor H; Arijs I; Thaunat O; Koenig A; Meas-Yedid V; Olivo-Marin JC; Halloran P; Chang J; Thorrez L; Kuypers D; Sprangers B; Van Lommel L; Schuit F; Essig M; Gwinner W; Anglicheau D; Marquet P; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2168-2183. PubMed ID: 32641395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
    Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.
    Viglietti D; Bouatou Y; Kheav VD; Aubert O; Suberbielle-Boissel C; Glotz D; Legendre C; Taupin JL; Zeevi A; Loupy A; Lefaucheur C
    Kidney Int; 2018 Oct; 94(4):773-787. PubMed ID: 29801667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.
    Lefaucheur C; Gosset C; Rabant M; Viglietti D; Verine J; Aubert O; Louis K; Glotz D; Legendre C; Duong Van Huyen JP; Loupy A
    Am J Transplant; 2018 Feb; 18(2):377-390. PubMed ID: 29086461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining.
    Akalin E; Dinavahi R; Dikman S; de Boccardo G; Friedlander R; Schroppel B; Sehgal V; Bromberg JS; Heeger P; Murphy B
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1261-7. PubMed ID: 17942771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The presence of anti-HLA donor-specific antibodies in lung allograft recipients does not correlate with C4d immunofluorescence in transbronchial biopsy specimens.
    Roberts JA; Barrios R; Cagle PT; Ge Y; Takei H; Haque AK; Burns KM; Land GA; Dilioglou S; Bernard DW
    Arch Pathol Lab Med; 2014 Aug; 138(8):1053-8. PubMed ID: 24164556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation.
    Cardarelli F; Pascual M; Tolkoff-Rubin N; Delmonico FL; Wong W; Schoenfeld DA; Zhang H; Cosimi AB; Saidman SL
    Transpl Int; 2005 May; 18(5):532-40. PubMed ID: 15819801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies.
    García-Carro C; Dörje C; Åsberg A; Midtvedt K; Scott H; Reinholt FP; Holdaas H; Seron D; Reisæter AV
    Transplantation; 2017 Jun; 101(6):1410-1415. PubMed ID: 27163535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathological analyses of interstitial fibrosis and tubular atrophy cases after kidney transplantation.
    Shimizu T; Toma H; Hayakawa N; Shibahara R; Ishiyama R; Hayashida A; Fujimori D; Tsunoyama K; Ikezawa E; Kitajima S; Iida S; Ishida H; Tanabe K; Honda K; Koike J
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():26-30. PubMed ID: 26972969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
    Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
    Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients.
    Dao M; Habès D; Taupin JL; Mussini C; Redon MJ; Suberbielle C; Jacquemin E; Gonzales E; Guettier C
    Liver Transpl; 2018 Jul; 24(7):897-907. PubMed ID: 29704327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rejection of the Renal Allograft in the Absence of Demonstrable Antibody and Complement.
    Zhao X; Huang G; Randhawa S; Zeng G; Lunz J; Randhawa P
    Transplantation; 2017 Feb; 101(2):395-401. PubMed ID: 26901079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.
    Lefaucheur C; Viglietti D; Hidalgo LG; Ratner LE; Bagnasco SM; Batal I; Aubert O; Orandi BJ; Oppenheimer F; Bestard O; Rigotti P; Reisaeter AV; Kamar N; Lebranchu Y; Duong Van Huyen JP; Bruneval P; Glotz D; Legendre C; Empana JP; Jouven X; Segev DL; Montgomery RA; Zeevi A; Halloran PF; Loupy A
    J Am Soc Nephrol; 2018 Feb; 29(2):620-635. PubMed ID: 29042454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.